Association between Liver Damage and Disease Progression Markers with Mortality Risk and Mechanical Ventilation in Hospitalized COVID-19 Patients: A Nationwide Retrospective SARSTer Study.
Humans
COVID-19
/ mortality
Retrospective Studies
Male
Female
Middle Aged
Biomarkers
/ blood
Aged
Respiration, Artificial
Liver Diseases
/ mortality
SARS-CoV-2
Disease Progression
Aspartate Aminotransferases
/ blood
L-Lactate Dehydrogenase
/ blood
Alanine Transaminase
/ blood
Prognosis
Adult
gamma-Glutamyltransferase
/ blood
Platelet Count
Hospitalization
Liver
/ pathology
Aged, 80 and over
COVID-19
SARS-CoV-2
alanine aminotransferase
artificial
aspartate aminotransferase
lactate dehydrogenases
liver
liver fibrosis
liver function tests
mortality
respiration
Journal
Viruses
ISSN: 1999-4915
Titre abrégé: Viruses
Pays: Switzerland
ID NLM: 101509722
Informations de publication
Date de publication:
27 Sep 2024
27 Sep 2024
Historique:
received:
12
08
2024
revised:
13
09
2024
accepted:
23
09
2024
medline:
26
10
2024
pubmed:
26
10
2024
entrez:
26
10
2024
Statut:
epublish
Résumé
(1) Background: Liver damage is an important component of acute COVID-19, and the advancement of preexisting liver disease is associated with a worse prognosis; (2) Methods: A nationwide retrospective study including 7444 patients aimed to evaluate levels of selected markers of liver damage and disease advancement and their association with mortality and mechanical ventilation (MV); (3) Results: Elevation of the following markers in multivariate models were associated with increased odds of mortality: Alanine transaminase (ALT), aspartate transaminase (AST), gamma-glutamyltransferase (GGT), lactate dehydrogenase (LDH), fibrosis-4 score (FIB-4), AST-to-platelet ratio index (APRI), and decreased levels of platelet count (PLT). Elevated levels of AST, LDH, APRI, FIB-4, and the AST/ALT ratio and decreased levels of PLT were associated with increased odds of MV in multivariate models. The best predictive accuracy against mortality was achieved with FIB-4 with AUC = 0.733 (95% CI, 0.718-0.749) at the optimal cut-off point of 2.764, while against MV was achieved with LDH with AUC = 0.753 (95% CI, 0.727-0.778) at the optimal cut-off point of 449.5 IU/L. (4) Conclusions: Our study confirms that the advancement of liver damage contributes to a worse prognosis in COVID-19 patients. Markers for liver damage and the advancement of liver disease can provide predictive value in clinical practice among COVID-19 patients.
Identifiants
pubmed: 39459864
pii: v16101530
doi: 10.3390/v16101530
pii:
doi:
Substances chimiques
Biomarkers
0
Aspartate Aminotransferases
EC 2.6.1.1
L-Lactate Dehydrogenase
EC 1.1.1.27
Alanine Transaminase
EC 2.6.1.2
gamma-Glutamyltransferase
EC 2.3.2.2
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : the Polish Association of Epidemiologists and Infectiologists
ID : the Polish Association of Epidemiologists and Infectiologists